How should tachycardia be treated in a patient with lung disease?

Treatment of Tachycardia in Patients with Lung Disease

In patients with lung disease who develop tachycardia, the first-line treatment is correction of hypoxemia and acidosis, followed by rate control with nondihydropyridine calcium channel antagonists (diltiazem or verapamil), while beta blockers, sotalol, propafenone, and adenosine should be avoided. 1

Primary Treatment Approach

Step 1: Correct Underlying Respiratory Pathophysiology

• Treat the underlying lung disease first - this is Class I recommendation 1, 2
• Correct hypoxemia and acid-base imbalance as primary therapeutic measures
• Antiarrhythmic drugs and cardioversion will likely be ineffective until respiratory decompensation is corrected 2
• Distinguish atrial fibrillation from multifocal atrial tachycardia (MAT), which is common in COPD and won't respond to cardioversion 2

Step 2: Identify and Remove Precipitating Factors

• Discontinue or reduce theophylline and beta-adrenergic agonists - these precipitate tachycardia and make rate control difficult 2, 1, 2
• These agents are Class III (not recommended) in patients with bronchospastic lung disease who develop AF 1

Pharmacologic Rate Control

First-Line Agent: Calcium Channel Blockers

Use diltiazem or verapamil for ventricular rate control (Class I recommendation) 1, 3

• These are the preferred agents because they don't exacerbate bronchospasm
• Effective for both atrial fibrillation and multifocal atrial tachycardia 4, 5
• Verapamil specifically shown to slow ventricular response in MAT 5

Agents to AVOID (Class III - Contraindicated)

The following are explicitly contraindicated in obstructive lung disease with tachycardia 1, 4:

• Non-selective beta blockers
• Sotalol
• Propafenone
• Adenosine

These agents can precipitate bronchospasm and are dangerous in this population.

Special Consideration: Beta-1 Selective Blockers

• Beta-1 selective blockers (e.g., bisoprolol, metoprolol) in small doses may be considered as an alternative if calcium channel blockers are insufficient 4
• This is a Class IIa recommendation
• Use with extreme caution and only if no active bronchospasm

Emergency Management

Hemodynamic Instability

Perform immediate direct-current cardioversion if the patient becomes hemodynamically unstable due to tachycardia (Class I recommendation) 1, 3

• Don't delay for pharmacologic attempts if patient is unstable
• This applies regardless of the specific arrhythmia type

Common Pitfalls to Avoid

1. Don't mistake MAT for atrial fibrillation - MAT won't respond to cardioversion and requires treatment of underlying disease plus calcium channel blockers 2, 6

2. Don't use digoxin as first-line - while not explicitly contraindicated, it's not recommended as initial therapy in this population

3. Don't attempt rhythm control before stabilizing respiratory status - antiarrhythmic therapy will be ineffective until hypoxia and acidosis are corrected 2

4. Don't use amiodarone, digoxin, or calcium channel blockers in pre-excited atrial fibrillation (Wolff-Parkinson-White) - these accelerate ventricular rate and are potentially harmful 2, 3

Clinical Algorithm Summary

1. Assess hemodynamic stability → If unstable: immediate cardioversion
2. If stable: Correct hypoxemia, acidosis, and treat underlying lung disease
3. Stop theophylline and beta-agonists if possible
4. Initiate diltiazem or verapamil for rate control
5. If inadequate response: Consider small doses of beta-1 selective blocker (with caution)
6. Distinguish AF from MAT on ECG - MAT shows ≥3 different P-wave morphologies and won't cardiovert

The evidence consistently emphasizes that respiratory optimization takes precedence over antiarrhythmic therapy in this population, and the choice of rate-controlling agent must account for the high risk of bronchospasm with traditional agents like non-selective beta blockers.